Abstract: Objective To estimate the effectiveness and safety of magnesium isoglycyrrhizinate injection （MIG） for the treatment of patients with cirrhosis. Methods All the randomized controlled trials（RCT） about the effectiveness and safety of MIG for the treatment of patients with cirrhosis were collected by searching databases including Pubmed，Embse，Cochrane library，CBM，Wanfang，CNKI and VIP. The screening of literatures，extraction of information and evaluation of the risk of bias were accomplished by two independent reviewers. Statistical analyses were performed with RevMan 5.2 software. Results A total of 9 RCTs involving 576 patients were included，while the methodology of the included studies was of low quality. The meta-analysis showed that the clinical effective rate of MIG used alone or in combination with other liver-protecting agents was significantly higher than in other hepatoprotective drugs （RR: 1.23，95%CI: 1.07 to 1.42，P<0.01） and （RR:1.31，95%CI: 1.13 to 1.51，P<0.01） with remarkably improved liver function and no severe side effects. Conclusion MIG injection is superior to other hepatoprotective drugs for liver cirrhosis with fewer side effects. However，more controlled trials of high quality are required to further assess the effectiveness and safety of MIG for patients with cirrhosis.

Key words: Cirrhosis, Magnesium isoglycyrrhizinate injection, Efficacy, Meta-analysis